SCHEMBL23384184

SCHEMBL23384184

C=C(CCNC(=O)COc1ccc(Cl)cc1)NC(=O)C1(N(C)C)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATF4 P18848 3/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ MCOLN3 Q8TDD5 1/20 0.44
▸ HDAC1 Q13547 1/20 0.43
▸ CASP2 P42575 1/20 0.43
▸ BCHE P06276 1/20 0.43
▸ ACHE P22303 1/20 0.43
▸ LMNA P02545 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ ADAMTS4 O75173 1/20 0.42
▸ MMP2 P08253 1/20 0.42
▸ MMP3 P08254 1/20 0.42
▸ MMP12 P39900 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23383999 0.87 ATF4 (0.49) ATF4CYP1A2CYP2C9CYP2C19HTT
SCHEMBL23384005 0.85 ATF4 (0.52) ATF4CYP1A2CYP2C9CYP2C19HTT
SCHEMBL23383781 0.83 MEN1 (0.48) CYP1A2CYP2C9CYP2C19HTTKDM4E
SCHEMBL23182908 0.83 KDM4E (0.54) ATF4CYP1A2CYP2C9CYP2C19HTT
SCHEMBL23384166 0.82 ATF4 (0.46) ATF4CYP1A2CYP2C9CYP2C19HTT
SCHEMBL23383744 0.82 HTT (0.57) CYP1A2CYP2C9CYP2C19HTTKDM4E
SCHEMBL23383871 0.81 ATF4 (0.47) ATF4CYP1A2CYP2C9CYP2C19HTT
SCHEMBL23383779 0.81 MEN1 (0.50) CYP1A2CYP2C9CYP2C19HTTKDM4E
SCHEMBL23384172 0.80 MEN1 (0.49) CYP1A2CYP2C9CYP2C19HTTKDM4E
SCHEMBL23384162 0.80 KMT2A (0.49) CYP1A2CYP2C9CYP2C19HTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210145771-A1 N-(3-(2-(4-CHLOROPHENOXY)ACETAMIDO)BICYCLO[1.1.1] PENTAN-1-YL)-2-CYCLOBUTANE-1- CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR TREATING CANCER AND OTHER DISEASES GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-05-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210145771-A1 N-(3-(2-(4-CHLOROPHENOXY)ACETAMIDO)BICYCLO[1.1.1] PENTAN-1-YL)-2-CYCLOBUTANE-1- CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR TREATING CANCER AND OTHER DISEASES ATF4, EIF2B1, EIF4A1 ATF4 1/4885CYP1A2 2327/4885CYP2C9 3589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback